Linnaeus Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel small-molecule oncology therapeutics. The company targets G protein-coupled receptors (GPCRs) to create treatments for cancers that are resistant to current therapies, with its lead candidate, LNS8801, currently in clinical trials.
LNS8801 is a first-in-class, orally bioavailable small molecule that acts as a potent and specific agonist of the G protein-coupled estrogen receptor (GPER). It is currently being evaluated in Phase 1/2 clinical trials for its effectiveness in treating various advanced cancers, both as a standalone therapy and in combination with other treatments.
LNS8801 is designed to address cancers that have become resistant to current therapies. It provides a potential new treatment option for patients with advanced malignancies, such as metastatic melanoma, who have progressed on or are unable to tolerate existing immunotherapies.
The primary problems addressed are cancer's resistance to existing treatments and the lack of therapeutic options for patients who experience significant immune-related adverse events from current immunotherapies.